Steven K. Libutti, MD, FACS, serves as Director of Rutgers Cancer Institute of New Jersey and Senior Vice President of Oncology Services for RWJBarnabas Health.
In these roles, Dr. Libutti oversees the state’s only National Cancer Institute-designated Comprehensive Cancer Center and the oncology service line of New Jersey’s largest healthcare system. Together these institutions provide pediatric and adult patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine. Rutgers Cancer Institute and RWJBarnabas Health are dedicated to improving the prevention, detection, treatment, and care of patients with cancer through the transformation of laboratory discoveries into clinical practice. Dr. Libutti also serves as Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences. He is a tenured Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at Rutgers School of Arts and Sciences.
Prior to joining Rutgers Cancer Institute and RWJBarnabas Health, Dr. Libutti served as Director of the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is a past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.
The recipient of funding from the National Cancer Institute for the past 24 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Dr. Libutti has published over 300 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds eleven U.S. patents.